petosemtamab
mAbexperimentalMulti-specific
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started May 2, 2018 (NCT03526835)
Timeline
Indications
Mechanism of action
EGFR inhibitor
LGR5 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297781 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06525220 | Phase 3 | Sep 25, 2024 | Merus Labs |
| NCT06496178 | Phase 3 | Jun 25, 2024 | Merus Labs |
| NCT03526835 | Phase 1 | May 2, 2018 | 4Clinics, Chiltern International, Merus Labs, Oncology Therapeutic Development, Q2 solutions |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merus Labs | For profit | 3 | 3 | 2 | 2018 |
| 4Clinics | For profit | 1 | 0 | 1 | 2018 |
| Chiltern International | For profit | 1 | 0 | 1 | 2018 |
| Oncology Therapeutic Development | For profit | 1 | 0 | 1 | 2018 |
| Q2 solutions | For profit | 1 | 0 | 1 | 2018 |
5 organizations
Page 1 / 1